- Home
- APLT vs SLRC Comparison
APLT vs SLRC Comparison
Compare APLT & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- SLRC
- Stock Information
- Founded
- APLT 2016
- SLRC 2007
- Country
- APLT United States
- SLRC United States
- Employees
- APLT N/A
- SLRC N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- SLRC Finance/Investors Services
- Sector
- APLT Health Care
- SLRC Finance
- Exchange
- APLT Nasdaq
- SLRC Nasdaq
- Market Cap
- APLT 971.6M
- SLRC 869.6M
- IPO Year
- APLT 2019
- SLRC 2010
- Fundamental
- Price
- APLT $8.69
- SLRC $16.16
- Analyst Decision
- APLT Strong Buy
- SLRC Sell
- Analyst Count
- APLT 5
- SLRC 4
- Target Price
- APLT $12.50
- SLRC $15.25
- AVG Volume (30 Days)
- APLT 1.8M
- SLRC 151.5K
- Earning Date
- APLT 11-07-2024
- SLRC 11-06-2024
- Dividend Yield
- APLT N/A
- SLRC 10.15%
- EPS Growth
- APLT N/A
- SLRC 34.63
- EPS
- APLT N/A
- SLRC 1.77
- Revenue
- APLT N/A
- SLRC $236,635,000.00
- Revenue This Year
- APLT N/A
- SLRC $3.60
- Revenue Next Year
- APLT $3,169.03
- SLRC N/A
- P/E Ratio
- APLT N/A
- SLRC $9.13
- Revenue Growth
- APLT N/A
- SLRC 5.79
- 52 Week Low
- APLT $1.79
- SLRC $14.41
- 52 Week High
- APLT $10.62
- SLRC $16.77
- Technical
- Relative Strength Index (RSI)
- APLT 46.34
- SLRC 67.11
- Support Level
- APLT $9.44
- SLRC $15.91
- Resistance Level
- APLT $10.62
- SLRC $16.14
- Average True Range (ATR)
- APLT 0.62
- SLRC 0.23
- MACD
- APLT -0.13
- SLRC 0.07
- Stochastic Oscillator
- APLT 14.95
- SLRC 96.55
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About SLRC SLR Investment Corp.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.